On February 19, the FDA approved acalabrutinib tablets and capsules in combination with venetoclax for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. For more information, read the FDA announcement and the AstraZeneca press release.
On February 19, the FDA approved acalabrutinib tablets and capsules in combination with venetoclax for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
For more information, read the FDA announcement and the AstraZeneca press release.
Posted on 2/20/2026
An at-home option for cervical cancer screening breaks down barriers to care and offers the same level of precision as screening in the clinic.
